Bovine serum albumin-modified prussian blue nanoparticles enhance wound healing through the promotion of skin angiogenesis

Chronic wounds and those that are resistant to healing represent significant challenges confronting the global medical community. Wound healing is a complex, continuous, and overlapping process; any disruption in this process can result in impaired wound healing and the development of chronic wounds. Notably, diminished angiogenesis plays a critical role in the progression of chronic, hard-to-heal wounds. In this study, we have engineered bovine serum albumin (BSA)-modified Prussian blue (PB) nanoparticles, which exhibit low toxicity. In vivo experiments demonstrated that compared to the control group, the BSA@PB treatment group significantly accelerated wound healing, enhanced epithelial regeneration, increased neovascularization, and promoted angiogenesis and collagen synthesis in the wound area. Furthermore, BSA@PB has been shown to possess excellent biocompatibility and safety. These findings suggest that BSA@PB nanoparticles can effectively promote angiogenesis to accelerate wound healing, offering a promising therapeutic strategy for preventing the formation of chronic wounds.